Commentary on "The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy." Choueiri TK, Xie W, Kollmannsberger C, North S, Knox JJ, Lampard JG, McDermott DF, Rini BI, Heng DY, Kidney Cancer Center, Dana Farber Cancer Institute, Boston, MA. J Urol 2011;185:60-6 (Epub 2010 Nov 12)

Stephen Boorjian

doi:10.1016/j.urolonc.2011.07.018

Commentary on "The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy." Choueiri TK, Xie W, Kollmannsberger C, North S, Knox JJ, Lampard JG, McDermott DF, Rini BI, Heng DY, Kidney Cancer Center, Dana Farber Cancer Institute, Boston, MA. J Urol 2011;185:60-6 (Epub 2010 Nov 12)

Stephen Boorjian

Urology

Research output: Contribution to journal › Short survey › peer-review

Original language	English (US)
Pages (from-to)	583-584
Number of pages	2
Journal	Urologic Oncology: Seminars and Original Investigations
Volume	29
Issue number	5
DOIs	https://doi.org/10.1016/j.urolonc.2011.07.018
State	Published - Sep 2011

ASJC Scopus subject areas

Oncology
Urology

Access to Document

10.1016/j.urolonc.2011.07.018

Cite this

Boorjian, S. (2011). Commentary on "The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy." Choueiri TK, Xie W, Kollmannsberger C, North S, Knox JJ, Lampard JG, McDermott DF, Rini BI, Heng DY, Kidney Cancer Center, Dana Farber Cancer Institute, Boston, MA. J Urol 2011;185:60-6 (Epub 2010 Nov 12). Urologic Oncology: Seminars and Original Investigations, 29(5), 583-584. https://doi.org/10.1016/j.urolonc.2011.07.018

Commentary on "The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy." Choueiri TK, Xie W, Kollmannsberger C, North S, Knox JJ, Lampard JG, McDermott DF, Rini BI, Heng DY, Kidney Cancer Center, Dana Farber Cancer Institute, Boston, MA. J Urol 2011;185:60-6 (Epub 2010 Nov 12). / Boorjian, Stephen.
In: Urologic Oncology: Seminars and Original Investigations, Vol. 29, No. 5, 09.2011, p. 583-584.

Research output: Contribution to journal › Short survey › peer-review

Boorjian, S 2011, 'Commentary on "The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy." Choueiri TK, Xie W, Kollmannsberger C, North S, Knox JJ, Lampard JG, McDermott DF, Rini BI, Heng DY, Kidney Cancer Center, Dana Farber Cancer Institute, Boston, MA. J Urol 2011;185:60-6 (Epub 2010 Nov 12)', Urologic Oncology: Seminars and Original Investigations, vol. 29, no. 5, pp. 583-584. https://doi.org/10.1016/j.urolonc.2011.07.018

Boorjian S. Commentary on "The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy." Choueiri TK, Xie W, Kollmannsberger C, North S, Knox JJ, Lampard JG, McDermott DF, Rini BI, Heng DY, Kidney Cancer Center, Dana Farber Cancer Institute, Boston, MA. J Urol 2011;185:60-6 (Epub 2010 Nov 12). Urologic Oncology: Seminars and Original Investigations. 2011 Sep;29(5):583-584. doi: 10.1016/j.urolonc.2011.07.018

Boorjian, Stephen. / Commentary on "The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy." Choueiri TK, Xie W, Kollmannsberger C, North S, Knox JJ, Lampard JG, McDermott DF, Rini BI, Heng DY, Kidney Cancer Center, Dana Farber Cancer Institute, Boston, MA. J Urol 2011;185:60-6 (Epub 2010 Nov 12). In: Urologic Oncology: Seminars and Original Investigations. 2011 ; Vol. 29, No. 5. pp. 583-584.

@article{6ce8fa9178ba4a4e8884a0654bfb382e,

title = "Commentary on {"}The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy.{"} Choueiri TK, Xie W, Kollmannsberger C, North S, Knox JJ, Lampard JG, McDermott DF, Rini BI, Heng DY, Kidney Cancer Center, Dana Farber Cancer Institute, Boston, MA. J Urol 2011;185:60-6 (Epub 2010 Nov 12)",

author = "Stephen Boorjian",

year = "2011",

month = sep,

doi = "10.1016/j.urolonc.2011.07.018",

language = "English (US)",

volume = "29",

pages = "583--584",

journal = "Urologic Oncology: Seminars and Original Investigations",

issn = "1078-1439",

publisher = "Elsevier Inc.",

number = "5",

}

TY - JOUR

T1 - Commentary on "The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy." Choueiri TK, Xie W, Kollmannsberger C, North S, Knox JJ, Lampard JG, McDermott DF, Rini BI, Heng DY, Kidney Cancer Center, Dana Farber Cancer Institute, Boston, MA. J Urol 2011;185:60-6 (Epub 2010 Nov 12)

AU - Boorjian, Stephen

PY - 2011/9

Y1 - 2011/9

UR - http://www.scopus.com/inward/record.url?scp=80052918870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052918870&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2011.07.018

DO - 10.1016/j.urolonc.2011.07.018

M3 - Short survey

AN - SCOPUS:80052918870

SN - 1078-1439

VL - 29

SP - 583

EP - 584

JO - Urologic Oncology: Seminars and Original Investigations

JF - Urologic Oncology: Seminars and Original Investigations

IS - 5

ER -

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this